Isabelle Ray-Coquard Selected Research

Asthenia

1/2021	Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2.
1/2020	Real-World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10.
11/2019	Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety.
11/2017	Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
1/2017	Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
12/2016	Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Isabelle Ray-Coquard Research Topics

Disease

122	Neoplasms (Cancer) 04/2022 - 06/2002
71	Ovarian Neoplasms (Ovarian Cancer) 02/2022 - 03/2003
57	Sarcoma (Soft Tissue Sarcoma) 01/2022 - 01/2004
30	Breast Neoplasms (Breast Cancer) 01/2022 - 10/2002
25	Carcinoma (Carcinomatosis) 02/2022 - 07/2006
16	Fatigue 01/2022 - 07/2009
16	Disease Progression 01/2022 - 05/2008
16	Neutropenia 01/2022 - 05/2006
13	Leiomyosarcoma 01/2022 - 08/2006
13	Hypertension (High Blood Pressure) 01/2021 - 07/2009
12	Anemia 01/2022 - 04/2003
12	Neoplasm Metastasis (Metastasis) 01/2022 - 08/2005
12	Ovarian Epithelial Carcinoma 11/2021 - 07/2014
12	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 01/2020 - 08/2005
10	Thrombocytopenia (Thrombopenia) 01/2022 - 10/2008
9	Nausea 01/2022 - 07/2009
9	Lymphopenia (Lymphocytopenia) 01/2022 - 12/2004
7	Endometrial Neoplasms (Endometrial Cancer) 01/2022 - 12/2013
6	Hemangiosarcoma (Angiosarcoma) 01/2022 - 11/2008
6	Asthenia 01/2021 - 12/2016
6	Vomiting 11/2020 - 12/2012
6	Osteosarcoma (Osteogenic Sarcoma) 01/2020 - 08/2012
5	Febrile Neutropenia 01/2022 - 12/2004
5	Proteinuria 11/2020 - 07/2009
5	Ewing Sarcoma (Sarcoma, Ewing) 01/2020 - 10/2008
5	Stomatitis 01/2019 - 08/2012
5	Renal Insufficiency (Renal Failure) 01/2016 - 01/2009
4	Diarrhea 01/2022 - 08/2012
4	Liposarcoma 12/2016 - 01/2004
4	Synovial Sarcoma (Synovioma) 12/2016 - 01/2004
4	Carcinogenesis 01/2015 - 05/2004
3	Hemorrhage 01/2022 - 07/2014
3	Fallopian Tube Neoplasms 12/2021 - 02/2014
3	Germ Cell and Embryonal Neoplasms (Germ Cell Tumor) 10/2021 - 01/2021
3	Colorectal Neoplasms (Colorectal Cancer) 04/2021 - 07/2007
3	Pathologic Complete Response 01/2021 - 08/2011

Drug/Important Bio-Agent (IBA)

50	PlatinumIBA 01/2022 - 03/2003
23	Paclitaxel (Taxol)FDA LinkGeneric 02/2022 - 03/2003
21	Bevacizumab (Avastin)FDA Link 01/2022 - 07/2007
21	Poly(ADP-ribose) Polymerase InhibitorsIBA 12/2021 - 01/2017
17	TrabectedinIBA 01/2022 - 10/2008
17	Imatinib Mesylate (Gleevec)FDA Link 01/2019 - 06/2002
16	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022 - 08/2006
13	Pharmaceutical PreparationsIBA 02/2021 - 01/2009
12	olaparibIBA 01/2022 - 12/2016
12	Biomarkers (Surrogate Marker)IBA 02/2021 - 05/2011
11	Carboplatin (JM8)FDA LinkGeneric 02/2022 - 02/2004
10	Hormones (Hormone)IBA 01/2022 - 07/2011
10	liposomal doxorubicin (Doxil)FDA Link 11/2021 - 10/2010
9	rucaparibIBA 12/2021 - 01/2017
9	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 07/2007
9	pazopanib FDA Link 01/2020 - 07/2009
8	Ifosfamide FDA LinkGeneric 10/2020 - 08/2006
7	Immune Checkpoint InhibitorsIBA 04/2022 - 01/2019
7	Tyrosine Kinase InhibitorsIBA 01/2022 - 03/2007
7	Biological ProductsIBA 01/2022 - 07/2007
7	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 12/2021 - 01/2017
7	Proteins (Proteins, Gene)FDA Link 04/2021 - 04/2008
7	taxaneIBA 01/2021 - 07/2004
6	Cisplatin (Platino)FDA LinkGeneric 10/2021 - 02/2004
6	HematinicsIBA 02/2012 - 03/2008
5	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2022 - 03/2015
5	cabozantinibIBA 01/2022 - 10/2014
5	IronIBA 01/2022 - 03/2008
5	AnthracyclinesIBA 07/2021 - 03/2003
5	CreatinineIBA 01/2021 - 01/2009
5	Hemoglobins (Hemoglobin)IBA 01/2021 - 08/2005
5	Sunitinib (Sutent)FDA Link 01/2016 - 03/2007
5	Docetaxel (Taxotere)FDA Link 01/2015 - 02/2004
5	Sorafenib (BAY 43-9006)FDA Link 11/2014 - 01/2012
4	Epoetin Alfa (Epogen)FDA Link 01/2022 - 03/2008
4	regorafenibIBA 01/2022 - 01/2015
4	1-dodecylpyridoxal (PLD)IBA 11/2021 - 10/2010
4	Alanine Transaminase (SGPT)IBA 01/2021 - 10/2008
4	Gemcitabine FDA Link 01/2021 - 08/2006
4	AntigensIBA 04/2020 - 03/2009
4	Phosphotransferases (Kinase)IBA 01/2020 - 03/2007
4	ErbB Receptors (EGF Receptor)IBA 06/2016 - 08/2012
4	EnzymesIBA 10/2010 - 05/2004
3	nintedanibIBA 02/2022 - 01/2016
3	lenvatinibIBA 01/2022 - 01/2021
3	pembrolizumabIBA 01/2022 - 01/2021
3	Aromatase InhibitorsIBA 01/2022 - 08/2012
3	Poly Adenosine Diphosphate RiboseIBA 12/2021 - 01/2017
3	Etoposide (VP 16)FDA LinkGeneric 10/2021 - 01/2020
3	Messenger RNA (mRNA)IBA 04/2021 - 08/2011
3	Everolimus FDA Link 01/2021 - 08/2012
3	Angiogenesis InhibitorsIBA 01/2021 - 07/2007
3	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 01/2007

Therapy/Procedure

84	Drug Therapy (Chemotherapy) 02/2022 - 01/2003
83	Therapeutics 02/2022 - 10/2002
8	Radiotherapy 01/2022 - 09/2005
6	Adjuvant Chemotherapy 01/2022 - 07/2004
6	Neoadjuvant Therapy 10/2020 - 05/2004
5	Immunotherapy 01/2022 - 01/2019
5	Combination Drug Therapy (Combination Chemotherapy) 01/2019 - 02/2004
4	Drug Tapering 01/2019 - 05/2006
3	Contraception (Birth Control) 01/2022 - 03/2018
3	Precision Medicine 01/2022 - 02/2021
3	Aftercare (After-Treatment) 10/2021 - 02/2008